REFERENCES
- Henriksson P, Blomback M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282–5.
- Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS. High dose polyestradiol phosphate with and without aceto-salicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 1989; 63: 512–4.
- Lukkarinen O, Kontturi M, and the Finnish Zoladex Multicentre Study Group. Comparison of a long-acting LHRH agonist and polyestradiol phosphate in the treatment of advanced prostatic carcinoma. Scand J Urol Nephrol 1994; 28: 171–8.
- Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two main-tenance-dose regimens. Prostate 1989; 14: 183–8.
- Henriksson P, Carlstrom K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, et al. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and cfin- ical effects, of a parenteral estrogen regimen. Prostate 1999; 40: 76–82.
- Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, et al. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988; 13: 257–61.
- Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000; 55: 328–33.
- Esposti P. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. Scand J Urol Nephrol 1971; 5: 199–209.
- Mostofi FK, Sesterhenn IA, Sobin LH. In: Histologic typing of prostate tumors. Geneva, Switzerland: edn World Health Organization, 1980: 17–21.
- Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017–21.
- Andersson L. Design of clinical trials on prostate cancer. Urology 1997; 49 (Suppl 4A): 39–45.
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
- Frödin T, Alund G, Varenhorst E. Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 1985; 7: 203–8.
- Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657–80.
- Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO. Parenteral polyestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 1998; 82: 63–8.
- Henriksson P, Blomback M, Bratt G, Edhag O, Eriksson A, Vesterquist O. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989; 3: 219–25.
- Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988; 49: 111–21.
- Hedlund PO, Gustafson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt (Etp or conventional estrogen. Scand J Urol Nephrol Suppl 1980; 55: 103.
- Eisen M, Napp HE, Vock R. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate. J Urol 1975; 114: 93–7.
- The Leuprolide Study Group. Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281.
- Cox RL, Crawford D. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991–8.
- Spetz AC, Hammar M, Lindberg B, Spangberg S, Varenhorst E. Prospective evaluation of hot flushes during treatment with parenteral estrogen or complete Scand J Urol Nephrol 36 androgen ablation for metastatic carcinoma of the prostate. J Urol 2001; 166: 517–20.